Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma.
Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy. The objective response rate was 48%, with 20% complete responses. The estimated median progression-free survival time was only five months (0.5 to 65 months) with estimated two- and five-year progression-free survival rates of 16 and 13%, respectively. The estimated median progression-free survival time was 24 months for complete responders; the progression-free survival times were significantly longer than the survival times (median = four months) for all other patients (P = .0002). Whether or not the addition of cytotoxic chemotherapy to progesterone hormonal therapy for metastatic endometrial carcinoma lengthens survival time is still open to question.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011446:Prospective Studies; D011897:Random Allocation; D013629:Tamoxifen / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D013629:Tamoxifen; D008525:Medroxyprogesterone; D008558:Melphalan; D005472:Fluorouracil